查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1631555

全球陣發性夜間血尿症治療市場：市場規模、佔有率和趨勢分析（按治療方法、地區和細分，2025-2030 年）

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Transplant, Blood Transfusion), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

陣發性夜間血尿症治療市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球陣發性夜間血尿症（PNH）治療市場規模預計到2030年將達到99.6億美元，2025年至2030年複合年成長率為9.6%。

推動市場發展的因素有幾個，包括血液和骨髓相關疾病的增加、老年人口的增加、新型治療劑的廣泛應用以及生物製藥的出現。

陣發性夜間血尿症(PNH) 是一種後天性慢性血液疾病。這是一種極為罕見的疾病，北美和歐洲已報告約 8,000 至 10,000 例病例。這種危及生命的疾病常表現為血栓症形成、持續性血管內溶血和全血細胞減少的三聯徵。儘管關於盛行率的資訊很少，但估計 PNH 影響著全世界超過 20,000 人，年發病率約為每百萬 1.3 人，盛行率約為每百萬 16 人。 PNH 對男性和女性都有影響。身體症狀可以出現在任何年齡，但通常在 30 至 40 歲之間出現。

包括單株抗體、重組蛋白和環肽在內的新型治療方法在新興市場中越來越受歡迎。但Soliris和其他候選藥物的治療費用較高，開發中地區的採用構成了障礙。預計在預測期內，輸血和支持性治療將因副作用和療效不佳而失去動力。

陣發性夜間血尿症治療市場：分析概述

  • 據估計，美國有 5,000 至 6,000 人患有 PNH，每年報告的新病例約為 450 例。
  • 由於美國治療費用高昂、各種在研藥物可能核准以及新型治療藥物的採用，美國將佔據全球 PNH 治療市場的大部分收益佔有率。
  • 2024 年，藥物治療佔據 PNH 市場的主導地位，比重超過 85.3%。除藥品外，預測期內幹細胞移植領域預計也將達到兩位數的成長。
  • 目前，有16種產品正在進行PNH治療的臨床評估，並處於不同的開發階段。 ALXN1210、Coversin、APL2 和 RA101495 等有前景的候選藥物在獲得監管部門核准後具有巨大的商業性潛力。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第3章陣發性夜間血尿症治療市場：促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章陣發性夜間血尿症治療市場：按治療方法的業務分析

  • 治療方法的市場佔有率（2024 年和 2030 年）
  • 治療方法儀表板
  • 市場規模預測及治療方法趨勢分析（2018-2030）
  • 劑量
  • 幹細胞移植
  • 輸血
  • 其他類型的治療

第5章陣發性夜間血尿症治療市場：按地區估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 按國家/地區分類（2018-2030 年）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類（2018-2030 年）
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類（2018-2030 年）
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 按國家/地區分類（2018-2030 年）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第6章 競爭格局

  • 參與企業概況
  • 公司市場地位分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Alexion Pharmaceuticals, Inc.
    • Apellis Pharmaceuticals
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Genentech, Inc.
    • BioCryst Pharmaceuticals, Inc.
    • Regeneron Pharmaceuticals Inc.
    • Sanofi
    • Pfizer Inc.
    • Amgen Inc.
Product Code: GVR-2-68038-622-6

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth & Trends:

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 9.96 billion by 2030, registering a CAGR of 9.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several factors such as rise in the number of blood and bone marrow related disorders, an increase in the geriatric population, wider adoption of novel therapeutics, and the emergence of biologics are driving the market.

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder. It is an ultra-rare disease with approximately 8,000 to 10,000 cases reported in North America and Europe. The life-threatening disease often manifests in three forms: thrombosis, persistent intravascular hemolysis, and pancytopenia. Although the information on its prevalence is scarce, PNH is estimated to affect more than 20,000 people worldwide with an incidence of about 1.3 per million annually and a prevalence of around 16 per million. PNH affects men and women equally. Although physical symptoms can begin at any age, they usually develop between 30-40 years of age.

Novel treatments including monoclonal antibodies, recombinant proteins, and cyclic peptides are gaining penetration in developed markets. However, the high cost of therapy with Soliris and other emerging pipeline drugs presents a barrier in adoption in developing regions. Blood transfusion and supportive care are anticipated to lose momentum during the forecast period due to adverse side effects and suboptimal efficacy.

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report Highlights:

  • An estimated 5,000 - 6,000 people in the U.S. suffer from PNH, with approximately 450 new cases being reported annually
  • U.S. dominated the global PNH treatment market dominated with a significant revenue share in 2024 due to the high cost of treatment in the U.S., potential approval of a range of pipeline drugs, and adoption of novel therapeutics
  • Treatment with medication dominated the PNH market with a share of more than 85.3% in 2024. Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period
  • Currently, 16 products are under clinical evaluation for PNH treatment in various stages of development. Promising pipeline candidates such as ALXN1210, Coversin, APL2, and RA101495 offer significant commercial potential post regulatory approval.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Billion)
  • 4.4. Medication
    • 4.4.1. Medication Market, 2018 - 2030 (USD Billion)
  • 4.5. Stem Cell Transplant
    • 4.5.1. Stem Cell Transplant Market, 2018 - 2030 (USD Billion)
  • 4.6. Blood Transfusion
    • 4.6.1. Blood Transfusion Market, 2018 - 2030 (USD Billion)
  • 4.7. Other Treatment Types
    • 4.7.1. Other Treatment Types Market, 2018 - 2030 (USD Billion)

Chapter 5. Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2024 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.4. North America
    • 5.4.1. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Regulatory Framework
      • 5.4.2.3. Competitive Insights
      • 5.4.2.4. U.S. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Regulatory Framework
      • 5.4.3.3. Competitive Insights
      • 5.4.3.4. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.4. Mexico
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Regulatory Framework
      • 5.4.4.3. Competitive Insights
      • 5.4.4.4. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Europe
    • 5.5.1. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 5.5.2. UK
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Regulatory Framework
      • 5.5.2.3. Competitive Insights
      • 5.5.2.4. UK Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.3. Germany
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Regulatory Framework
      • 5.5.3.3. Competitive Insights
      • 5.5.3.4. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.4. France
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Regulatory Framework
      • 5.5.4.3. Competitive Insights
      • 5.5.4.4. France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.5. Italy
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Regulatory Framework
      • 5.5.5.3. Competitive Insights
      • 5.5.5.4. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.6. Spain
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Regulatory Framework
      • 5.5.6.3. Competitive Insights
      • 5.5.6.4. Spain Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.7. Norway
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Regulatory Framework
      • 5.5.7.3. Competitive Insights
      • 5.5.7.4. Norway Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.8. Denmark
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Regulatory Framework
      • 5.5.8.3. Competitive Insights
      • 5.5.8.4. Denmark Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.5.9. Sweden
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Regulatory Framework
      • 5.5.9.3. Competitive Insights
      • 5.5.9.4. Sweden Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 5.6. Asia Pacific
    • 5.6.1. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.2. Japan
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Regulatory Framework
      • 5.6.2.3. Competitive Insights
      • 5.6.2.4. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Regulatory Framework
      • 5.6.3.3. Competitive Insights
      • 5.6.3.4. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.4. India
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Regulatory Framework
      • 5.6.4.3. Competitive Insights
      • 5.6.4.4. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.5. South Korea
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Regulatory Framework
      • 5.6.5.3. Competitive Insights
      • 5.6.5.4. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.6. Australia
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Regulatory Framework
      • 5.6.6.3. Competitive Insights
      • 5.6.6.4. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.6.7. Thailand
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Regulatory Framework
      • 5.6.7.3. Competitive Insights
      • 5.6.7.4. Thailand Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Latin America
    • 5.7.1. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 5.7.2. Brazil
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Regulatory Framework
      • 5.7.2.3. Competitive Insights
      • 5.7.2.4. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Regulatory Framework
      • 5.7.3.3. Competitive Insights
      • 5.7.3.4. Argentina Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8. MEA
    • 5.8.1. MEA Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 5.8.2. South Africa
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Regulatory Framework
      • 5.8.2.3. Competitive Insights
      • 5.8.2.4. South Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.8.3. Saudi Arabia
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Regulatory Framework
      • 5.8.3.3. Competitive Insights
      • 5.8.3.4. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.8.4. UAE
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Regulatory Framework
      • 5.8.4.3. Competitive Insights
      • 5.8.4.4. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.8.5. Kuwait
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Regulatory Framework
      • 5.8.5.3. Competitive Insights
      • 5.8.5.4. Kuwait Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. Alexion Pharmaceuticals, Inc.
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Treatment Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Apellis Pharmaceuticals
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Treatment Benchmarking
      • 6.5.2.4. Strategic Initiatives
    • 6.5.3. Novartis AG
      • 6.5.3.1. Overview
      • 6.5.3.2. Financial Performance
      • 6.5.3.3. Treatment Benchmarking
      • 6.5.3.4. Strategic Initiatives
    • 6.5.4. F. Hoffmann-La Roche Ltd
      • 6.5.4.1. Overview
      • 6.5.4.2. Financial Performance
      • 6.5.4.3. Treatment Benchmarking
      • 6.5.4.4. Strategic Initiatives
    • 6.5.5. Genentech, Inc.
      • 6.5.5.1. Overview
      • 6.5.5.2. Financial Performance
      • 6.5.5.3. Treatment Benchmarking
      • 6.5.5.4. Strategic Initiatives
    • 6.5.6. BioCryst Pharmaceuticals, Inc.
      • 6.5.6.1. Overview
      • 6.5.6.2. Financial Performance
      • 6.5.6.3. Treatment Benchmarking
      • 6.5.6.4. Strategic Initiatives
    • 6.5.7. Regeneron Pharmaceuticals Inc.
      • 6.5.7.1. Overview
      • 6.5.7.2. Financial Performance
      • 6.5.7.3. Treatment Benchmarking
      • 6.5.7.4. Strategic Initiatives
    • 6.5.8. Sanofi
      • 6.5.8.1. Overview
      • 6.5.8.2. Financial Performance
      • 6.5.8.3. Treatment Benchmarking
      • 6.5.8.4. Strategic Initiatives
    • 6.5.9. Pfizer Inc.
      • 6.5.9.1. Overview
      • 6.5.9.2. Financial Performance
      • 6.5.9.3. Treatment Benchmarking
      • 6.5.9.4. Strategic Initiatives
    • 6.5.10. Amgen Inc.
      • 6.5.10.1. Overview
      • 6.5.10.2. Financial Performance
      • 6.5.10.3. Treatment Benchmarking
      • 6.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global paroxysmal nocturnal hemoglobinuria treatment market, by region, 2018 - 2030 (USD Billion)
  • Table 4. Global paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 5. North America paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 6. North America paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 7. U.S. paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 8. Canada paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 9. Mexico paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 10. Europe paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 11. Europe paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 12. UK paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 13. Germany paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 14. France paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 15. Italy paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 16. Spain paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 17. Norway paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 18. Denmark paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 19. Sweden paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 20. Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 21. Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 22. Japan paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 23. China paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018-2030 (USD Billion)
  • Table 24. India paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 25. Australia paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 26. South Korea paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 27. Thailand paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 28. Latin America paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 29. Latin America paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 30. Brazil paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 31. Argentina paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 32. Middle East & Africa paroxysmal nocturnal hemoglobinuria treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 33. Middle East & Africa paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 34. South Africa paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 35. Saudi Arabia paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 36. UAE paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 37. Kuwait paroxysmal nocturnal hemoglobinuria treatment market, by treatment, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Paroxysmal Nocturnal Hemoglobinuria Treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment outlook (USD Billion)
  • Fig. 10 Competitive landscape
  • Fig. 11 Paroxysmal Nocturnal Hemoglobinuria Treatment market dynamics
  • Fig. 12 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Porter's five forces analysis
  • Fig. 13 Paroxysmal Nocturnal Hemoglobinuria Treatment market: PESTLE analysis
  • Fig. 14 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Treatment segment dashboard
  • Fig. 15 Paroxysmal Nocturnal Hemoglobinuria Treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 16 Medication market, 2018 - 2030 (USD Billion)
  • Fig. 17 Stem cell transplant market, 2018 - 2030 (USD Billion)
  • Fig. 18 Blood transfusion market, 2018 - 2030 (USD Billion)
  • Fig. 19 Other treatment types market, 2018 - 2030 (USD Billion)
  • Fig. 20 Paroxysmal Nocturnal Hemoglobinuria Treatment market revenue, by region
  • Fig. 21 Regional marketplace: Key takeaways
  • Fig. 22 North America paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 23 U.S. country dynamics
  • Fig. 24 U.S. paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 25 Canada country dynamics
  • Fig. 26 Canada paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 27 Mexico country dynamics
  • Fig. 28 Mexico paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 29 Europe paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 30 UK country dynamics
  • Fig. 31 UK paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 32 Germany country dynamics
  • Fig. 33 Germany paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 34 France country dynamics
  • Fig. 35 France paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 36 Italy country dynamics
  • Fig. 37 Italy paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 38 Spain country dynamics
  • Fig. 39 Spain paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 40 Norway country dynamics
  • Fig. 41 Norway paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 42 Sweden country dynamics
  • Fig. 43 Sweden paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 44 Denmark country dynamics
  • Fig. 45 Denmark paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 46 Asia Pacific paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 47 Japan country dynamics
  • Fig. 48 Japan paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 49 China country dynamics
  • Fig. 50 China paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 51 India country dynamics
  • Fig. 52 India paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 53 Australia country dynamics
  • Fig. 54 Australia paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 55 South Korea country dynamics
  • Fig. 56 South Korea paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 57 Thailand country dynamics
  • Fig. 58 Thailand paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 59 Latin America paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 60 Brazil country dynamics
  • Fig. 61 Brazil paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 62 Argentina country dynamics
  • Fig. 63 Argentina paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 64 MEA paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 65 South Africa country dynamics
  • Fig. 66 South Africa paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 67 Saudi Arabia country dynamics
  • Fig. 68 Saudi Arabia paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 69 UAE country dynamics
  • Fig. 70 UAE paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 71 Kuwait country dynamics
  • Fig. 72 Kuwait paroxysmal nocturnal hemoglobinuria treatment market, 2018 - 2030 (USD Billion)
  • Fig. 73 Company categorization
  • Fig. 74 Company market position analysis
  • Fig. 75 Strategic framework